A growing share of the pharmaceutical development pipeline is occupied by macromolecule drugs, which are primarily administered by injection. Despite decades of attempts, non-invasive delivery of macromolecules has seen only a few success stories. Potential benefits of non-invasive administration include better patient acceptance and adherence and potentially better efficacy and safety. Greater inter-disciplinary dialogue and collaboration are integral to realizing these benefits.
blood-brain barrier drug delivery in vitro models macromolecules permeation enhancers
This is a preview of subscription content, log in to check access.
Acknowledgments and Disclosures
RS and CS are employees of Catalent Pharma Solutions.
Moroz E, Matoori S, Leroux JC. Oral delivery of macromolecular drugs: where we are after almost 100years of attempts. Adv Drug Deliv Rev. 2016;101:108–21.CrossRefPubMedGoogle Scholar
Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003;2(4):289–95.CrossRefPubMedGoogle Scholar
Butler JM, Dressman JB. The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci. 2010;99(12):4940–54.CrossRefPubMedGoogle Scholar
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26.CrossRefPubMedGoogle Scholar